title: Successful Additional Corticosteroid Treatment in a Patient with Mycoplasma pneumoniae Pneumonia in whom a Monobacterial Infection was Confirmed by a Molecular Method Using Bronchoalveolar Lavage Fluid.
abstract: A 23-year-old Japanese woman was admitted to A hospital due to pneumonia. IgM for Mycoplasma pneumoniae was positive, and the patient was treated with imipenem/cilastatin, clindamycin, pazufloxacin and minocycline. However, both the chest radiological findings and the symptoms became exacerbated, and she was therefore transferred to our hospital. The bronchoalveolar lavage fluid was obtained, and a 16S rRNA gene sequencing analysis revealed a monobacterial infection of Mycoplasma pneumoniae. Therefore, corticosteroid treatment in addition to minocycline was administered, and the patients symptoms, laboratory data and chest radiographs improved. Corticosteroid therapy may therefore be considered for patients with refractory M. pneumoniae pneumonia.
authors.affiliation: Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan.
authors.forename: Kei
authors.initials: K
authors.lastname: Yamasaki
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yatera
authors.forename: Kaori
authors.initials: K
authors.lastname: Kato
authors.forename: Shingo
authors.initials: S
authors.lastname: Noguchi
authors.forename: Toshinori
authors.initials: T
authors.lastname: Kawanami
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Fukuda
authors.forename: Keisuke
authors.initials: K
authors.lastname: Naito
authors.forename: Kentaro
authors.initials: K
authors.lastname: Akata
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ishimoto
authors.forename: Hatsumi
authors.initials: H
authors.lastname: Taniguchi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Mukae
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000382:microbiology*; D015377:Cilastatin / Q000008:administration & dosage; D000077728:Cilastatin, Imipenem Drug Combination; D002981:Clindamycin / Q000008:administration & dosage; D018450:Disease Progression; D004338:Drug Combinations; D024881:Drug Resistance, Bacterial; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage; D008911:Minocycline / Q000008:administration & dosage; D009177:Mycoplasma pneumoniae / Q000235:genetics / Q000302:isolation & purification*; D010078:Oxazines / Q000008:administration & dosage; D011019:Pneumonia, Mycoplasma / Q000175:diagnosis* / Q000188:drug therapy; D012336:RNA, Ribosomal, 16S / Q000302:isolation & purification*; D013902:Radiography, Thoracic; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D024841:Fluoroquinolones; D010078:Oxazines; D012336:RNA, Ribosomal, 16S; D015377:Cilastatin; D002981:Clindamycin; C078052:pazufloxacin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination; D008911:Minocycline